The global Infectious Respiratory Disease Diagnostics market size was valued at approximately USD 11,800 Million in 2025 and is projected to reach USD 16,270 Million by 2035, expanding at a CAGR of 3.28% from 2026 to 2035.
Market Overview
The global Infectious Respiratory Disease Diagnostics Market is witnessing steady growth due to the increasing prevalence of respiratory infections, including influenza, COVID-19, tuberculosis (TB), respiratory syncytial virus (RSV), and bacterial pneumonia. The growing need for early disease detection, accurate pathogen identification, and effective infection control is encouraging healthcare providers to adopt advanced diagnostic solutions.
According to BrandEssence® Market Research, the market is projected to grow from USD 11,800 Million in 2025 to USD 16,270 Million by 2035, registering a CAGR of 3.28% during 2026–2035.
Growth Drivers & Trends
The increasing global burden of infectious respiratory diseases is a major factor driving market growth. Seasonal influenza outbreaks, tuberculosis cases, COVID-19 infections, and RSV-related illnesses are increasing the demand for reliable diagnostic testing.
Technological advancements in molecular diagnostics, polymerase chain reaction (PCR), nucleic acid amplification tests (NAAT), and multiplex testing are improving diagnostic accuracy and turnaround times. Healthcare facilities are increasingly adopting point-of-care testing to support faster clinical decisions.
Additionally, expanding public health surveillance programs, growing awareness of early diagnosis, and investments in decentralized testing solutions are creating new market opportunities. However, high equipment costs, regulatory complexities, and limited diagnostic infrastructure in developing regions remain significant challenges.
Market Segmentation
The Infectious Respiratory Disease Diagnostics Market is segmented by product type, disease, technology, and end use.
By Product Type: Molecular Diagnostics (PCR/NAAT), Rapid Antigen Detection Tests, Serology/Immunoassay Tests, Imaging-Aided Diagnostics, Point-of-Care Tests, and Others.
By Disease: Influenza, COVID-19/SARS-CoV-2, Tuberculosis (TB), Respiratory Syncytial Virus (RSV), Bacterial Pneumonia, and Others.
By Technology: Nucleic Acid Amplification Tests (NAATs)/PCR, Rapid Antigen Detection, Next-Generation Sequencing (NGS), Immunofluorescence Assay (IFA), and Loop-Mediated Isothermal Amplification (LAMP).
By End Use: Hospitals and Diagnostic Centers, Clinical and Reference Laboratories, Academic and Research Institutes, Public Health and Government Agencies, Home/Self-Testing, and Pharmaceutical and Biotechnology Companies.
In 2025, Molecular Diagnostics held the largest product-type share at 42.60%. The Influenza/COVID-19 combined disease category accounted for 30.40%, while NAAT/PCR dominated technology with 44.20%. Hospitals and Diagnostic Centers represented 38.90% of the end-use market.
Regional Analysis
North America dominated the global market in 2025, accounting for 37.60% of the market share, supported by advanced healthcare infrastructure, strong diagnostic capabilities, and established molecular testing facilities.
Europe represented 28.50% of the global market, driven by established laboratory networks and increasing adoption of advanced respiratory diagnostic technologies.
Asia Pacific accounted for 23.80% of the market in 2025 and is expected to experience significant growth. China is projected to increase its regional market share from 32.70% in 2025 to 35.20% by 2032. India is another important growth market.
Latin America and the Middle East & Africa are also expected to offer growth opportunities through expanding healthcare infrastructure and improving access to diagnostic services.
Competitive Landscape
The competitive landscape is characterized by technological innovation, product development, molecular diagnostic advancements, and strategic investments in respiratory testing solutions. Market participants are focusing on improving testing accuracy, developing multiplex diagnostic platforms, and expanding point-of-care testing capabilities.
Get the Complete Market Report – Buy Now
Key Players
Major companies operating in the Infectious Respiratory Disease Diagnostics Market include:
- Abbott Laboratories
- Thermo Fisher Scientific
- F. Hoffmann-La Roche Ltd.
- bioMérieux SA
- Becton, Dickinson and Company
- Danaher Corporation
- Siemens Healthineers
- QIAGEN
- Hologic
- Bio-Rad Laboratories
- QuidelOrtho
- DiaSorin
- Seegene
- Cepheid
- SD Biosensor
Recent Developments
- October 2024: The FDA granted traditional marketing authorization to the Haagen Rapid Check COVID-19/Flu A&B Antigen Test, supporting the availability of combined home testing.
- September 2024: Roche launched its cobas Respiratory flex test featuring TAGS multiplex PCR technology, capable of identifying up to 15 pathogens in a single PCR test.
- 2024: Updated CDC guidance highlighted the importance of molecular multiplex testing for detecting influenza, SARS-CoV-2, and RSV in patients with acute respiratory illness.
- 2024: The WHO reiterated its target of achieving 100% coverage of recommended rapid molecular diagnostics for newly diagnosed TB cases by 2027.
Frequently Asked Questions (FAQs)
- What is the global Infectious Respiratory Disease Diagnostics Market size in 2025?
The global market was valued at approximately USD 11,800 Million in 2025.
- What will be the market size by 2035?
The market is projected to reach USD 16,270 Million by 2035.
- What is the expected CAGR during 2026–2035?
The market is expected to expand at a CAGR of 3.28%.
- Which region dominates the Infectious Respiratory Disease Diagnostics Market?
North America dominated the market with a 37.60% share in 2025.
- Who are the major players in this market?
Major players include Abbott Laboratories, Thermo Fisher Scientific, Roche, bioMérieux, Danaher Corporation, Siemens Healthineers, QIAGEN, and Bio-Rad Laboratories.
About Us
BrandEssence® Market Research is a market intelligence and consulting organization providing comprehensive market research reports, industry analysis, competitive intelligence, and strategic insights across multiple industries. The company delivers data-driven research to help businesses understand market dynamics, identify growth opportunities, and make informed strategic decisions.
Contact Us
BrandEssence® Market Research and Consulting Pvt. Ltd.
Website: https://brandessenceresearch.com/
Phone No: +91 8975852287
Email: sales@brandessenceresearch.com
Website: https://brandessenceresearch.com/
